2.30
-0.007(-0.30%)
Currency In USD
| Previous Close | 2.31 |
| Open | 2.29 |
| Day High | 2.35 |
| Day Low | 2.29 |
| 52-Week High | 10.16 |
| 52-Week Low | 2.08 |
| Volume | 7,289 |
| Average Volume | 105,868 |
| Market Cap | 6.61M |
| PE | -1.51 |
| EPS | -1.53 |
| Moving Average 50 Days | 2.67 |
| Moving Average 200 Days | 3.51 |
| Change | -0.01 |
If you invested $1000 in Biomerica, Inc. (BMRA) 10 years ago, it would be worth $303.03 as of December 05, 2025 at a share price of $2.303. Whereas If you bought $1000 worth of Biomerica, Inc. (BMRA) shares 5 years ago, it would be worth $39.71 as of December 05, 2025 at a share price of $2.303.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
GlobeNewswire Inc.
Nov 25, 2025 1:19 PM GMT
Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
GlobeNewswire Inc.
Nov 06, 2025 1:19 PM GMT
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BM
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
GlobeNewswire Inc.
Oct 16, 2025 12:19 PM GMT
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIR